Core Viewpoint - Baxter International has revised its forecasts for adjusted annual profit and revenue growth downward after missing third-quarter revenue estimates due to ongoing impacts from hurricane-related disruptions [1] Financial Performance - The company reported a revenue miss in the third quarter, which has led to a reassessment of its financial outlook for the year [1] - Adjusted annual profit and revenue growth forecasts have been trimmed as a result of these challenges [1] External Factors - Persistent impacts from hurricane-related disruptions have significantly affected the company's operations and financial performance [1]

Sales Performance - Third-quarter sales from continuing operations totaled approximately $2.84 billion, increasing 5% on a reported basis and 2% on an operational basis[4] - U.S. sales from continuing operations totaled approximately $1.54 billion, increasing 3% on a reported basis but declining 1% on an operational basis[8] - International sales from continuing operations reached approximately $1.29 billion, increasing 8% on a reported basis and 5% on an operational basis[8] - Medical Products & Therapies sales for the third quarter were approximately $1.33 billion, declining 1% on both a reported and operational basis[7] - Healthcare Systems & Technologies sales for the third quarter totaled approximately $773 million, increasing 3% on a reported basis[10] - Pharmaceuticals sales for the third quarter were approximately $632 million, reflecting a 7% increase on both a reported and operational basis[10] - Infusion Therapies & Technologies segment sales decreased by 4% to $1,023 million in Q3 2025 from $1,070 million in Q3 2024[44] - Advanced Surgery segment sales increased by 13% to $306 million in Q3 2025, up from $272 million in Q3 2024[44] - The Medical Products & Therapies segment reported sales of $1,329 million in Q3 2025, a slight decrease of 1% from $1,342 million in Q3 2024[44] - The Healthcare Systems & Technologies segment achieved sales of $773 million in Q3 2025, reflecting a 3% increase from $752 million in Q3 2024[44] - The Pharmaceuticals segment's sales rose by 7% to $632 million in Q3 2025, compared to $588 million in Q3 2024[44] - For the three months ended September 30, 2025, total net sales growth for continuing operations was reported at 5%, with operational sales growth at 2%[53] - For the nine months ended September 30, 2025, total net sales growth was 5%, with operational sales growth at 2%[55] Earnings and Income - Adjusted diluted earnings per share (EPS) from continuing operations for the third quarter was $0.69, representing a 41% increase over the prior year[8] - Income (loss) from continuing operations was $(51) million, compared to $61 million in Q3 2024[28] - Adjusted income (loss) from continuing operations (excluding special items) rose by 40% to $353 million, compared to $252 million in the previous year[28] - Adjusted diluted EPS from continuing operations (excluding special items) increased by 41% to $0.69, up from $0.49[28] - The company reported a net income of $171 million for the nine months ended September 30, 2025, compared to a net loss of $128 million in 2024[35] - Diluted earnings per share from continuing operations increased by 40% to $1.83 from $1.31 in the previous year[35] - The company's net income for the nine months ended September 30, 2025, was $1,238 million, with diluted earnings per share of $1.85, reflecting a gross margin of 40.6%[37] - Adjusted diluted EPS guidance for FY 2025 is projected to be between $2.35 and $2.40[56] Costs and Expenses - Cost of sales increased by 13% to $1,885 million, compared to $1,666 million in the previous year[28] - Gross margin decreased by 8% to $950 million, with a gross margin percentage of 33.5%, down from 38.3%[28] - The company incurred $96 million in intangible asset amortization during the quarter[30] - The company incurred restructuring and business optimization costs related to the sale of its former Kidney Care segment and product line exits in 2024[33] - The company faced significant costs to comply with new European medical device regulations, which are considered a one-time regulatory change[33] - The company incurred costs related to centralizing research and development activities in 2024, impacting discontinued operations[39] - The company faced significant costs related to Hurricane Helene, impacting both continuing and discontinued operations in 2025[44] Future Projections - For full-year 2025, Baxter expects sales growth from continuing operations of 4% to 5% on a reported basis and 1% to 2% on an operational basis[12] - The company expects fourth-quarter 2025 sales growth from continuing operations of approximately 2% on a reported basis and a decline of approximately 2% on an operational basis[13] - The company projects a U.S. GAAP sales growth of approximately 2% for Q4 2025, with operational sales growth expected to be around -2%[56] - The exit of IV Solutions in China is expected to impact sales growth by approximately 50 basis points in FY 2025[56] - Foreign exchange effects are anticipated to reduce sales growth by approximately 100 basis points in Q4 2025 and 50 basis points for FY 2025[56] Special Items and Adjustments - Business optimization items contributed $25 million to the income, with a net impact of $0.05 per share[30] - The company reported a gain of $37 million from the sale of Kidney Care, impacting earnings by $0.07 per share[30] - Tax matters resulted in a net impact of $(213) million, affecting earnings by $(0.07) per share[30] - Special items included in the results for 2025 amounted to $1,082 million, impacting the net income attributable to Baxter stockholders, which was $1,087 million for the same period[38] - The effective tax rate for income tax expense was reported at 30.2% for the nine months ended September 30, 2025[38] - The effective tax rate for income tax expense was 4.3%[30] - The effective tax rate for income tax expense in 2024 was reported at (1.6)%[38] Operational Efficiency - Operating income rose by 11% to $172 million, representing 6.1% of net sales, compared to 5.7% in Q3 2024[28] - Interest expense decreased by 33% to $58 million, down from $87 million in the prior year[28] - The company experienced a 142.1% increase in operating income before income taxes, reflecting improved operational efficiency[30] - Adjusted operating income (excluding special items) increased by 8% to $423 million, up from $391 million[28] - Adjusted operating income (excluding special items) increased by 17% to $1,238 million from $1,055 million in the previous year[35] Shareholder Information - Net income attributable to Baxter stockholders was $(46) million, a significant decrease from $140 million in Q3 2024[28] - The weighted-average diluted shares as reported were 514 million, with adjusted shares at 515 million[30] - The company reported a gross margin of 38.4% for the nine months ended September 30, 2024, with a net income of $(128) million[38] - The adjusted net income for the nine months ended September 30, 2025, was $1,096 million, with adjusted diluted earnings per share of $2.13[38]

Core Insights - Baxter International Inc. reported its third-quarter 2025 financial results, highlighting a significant increase in adjusted net income and earnings per share, alongside a strategic focus on continuous improvement and growth initiatives [1][4][11]. Financial Performance - The company reported third-quarter sales from continuing operations of approximately $2.84 billion, representing a 5% increase on a reported basis and a 2% increase on an operational basis [11][12]. - Adjusted net income from continuing operations was $0.69 per diluted share, marking a 41% increase compared to the previous year [4][11]. - U.S. GAAP diluted earnings per share from continuing operations was reported at a loss of $0.10, while adjusted diluted EPS from continuing operations was $0.69 [11][12]. Segment Results - Medical Products & Therapies sales totaled approximately $1.33 billion, declining 1% on both a reported and operational basis, primarily due to reduced sales in the Infusion Therapies & Technologies division [12]. - Healthcare Systems & Technologies sales reached approximately $773 million, increasing 3% on a reported basis and 2% on an operational basis, driven by demand for Care & Connectivity Solutions [12]. - Pharmaceuticals sales amounted to approximately $632 million, reflecting a 7% increase on both a reported and operational basis, supported by strong performance in Drug Compounding and Injectables & Anesthesia products [12]. Strategic Initiatives - The company has launched a new enterprise-wide continuous improvement system aimed at enhancing execution and strengthening future results [2]. - Baxter expects full-year 2025 sales growth from continuing operations to be between 4% to 5% on a reported basis and 1% to 2% on an operational basis, with adjusted earnings from continuing operations projected at $2.35 to $2.40 per diluted share [6][7]. - For the fourth quarter of 2025, Baxter anticipates sales growth from continuing operations of approximately 2% on a reported basis and a decline of about 2% on an operational basis [7].

Core Viewpoint - Baxter International, Inc. is facing a class action lawsuit due to allegations of systemic defects in its Novum IQ Large Volume Pump, which resulted in serious patient risks and a significant drop in stock price following the announcement of a pause in shipments [3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled Electrical Workers Pension Fund, Local 103, I.B.E.W. v. Baxter International, Inc., and covers purchasers of Baxter common stock from February 23, 2022, to July 30, 2025 [1]. - Investors have until December 15, 2025, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit alleges that Baxter made false or misleading statements regarding the safety and functionality of its Novum LVP, which led to malfunctions and patient risks [3]. Group 2: Allegations Against Baxter - Specific allegations include that Baxter was aware of multiple malfunctions and injuries related to the Novum LVP but failed to adequately address these issues [3]. - The lawsuit claims that Baxter's customer alerts were insufficient and that design flaws persisted, leading to serious harm [3]. - Following Baxter's announcement on July 31, 2025, to pause shipments of the Novum LVP, the company's stock price fell by more than 22% [4]. Group 3: Legal Process and Representation - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Baxter common stock during the class period to seek lead plaintiff status [5]. - The lead plaintiff will represent the interests of all class members and can select a law firm to litigate the case [5]. Group 4: Company Background - Robbins Geller Rudman & Dowd LLP is a leading firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [6]. - The firm has a strong track record, including securing the largest securities class action recovery in history at $7.2 billion in the Enron case [6].

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming December 15, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Baxter International, Inc. ("Baxter†or the "Company†) (NYSE: BAX) common stock between February 23, 2022 and July 30, 2025, inclusive (the "Class Period†). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN BAXTER INTERNATIONAL, INC. (BAX), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTI. ...

Core Viewpoint - Baxter International, Inc. is facing a federal securities class action lawsuit due to safety concerns regarding its Novum IQ Large Volume Pump, which has been linked to serious patient injuries and deaths, leading to a significant decline in the company's stock price [4][5]. Summary by Sections Incident Overview - On April 7, 2025, safety issues regarding Baxter's Novum IQ Large Volume Pump emerged after a whistleblower reported inaccuracies in infusion [4]. - Baxter issued warning letters on April 24 and July 14, 2025, acknowledging risks of underinfusion and overinfusion, with reports of 79 serious injuries and two patient deaths [4]. - Following the announcement of a temporary pause in shipments on July 31, 2025, Baxter's stock price fell by $6.29, approximately 22.4%, from $28.05 to $21.76 [4]. Lawsuit Details - The lawsuit is on behalf of investors who purchased Baxter securities from February 23, 2022, to July 30, 2025 [5]. - Allegations include failure to disclose systemic defects in the Novum LVP, inadequate responses to reported malfunctions, and the heightened risk of halting new sales of the pumps [5].

Core Viewpoint - A class action lawsuit has been filed against Baxter International, Inc. for securities fraud, related to safety issues with its Novum IQ Large Volume Pump, which has led to significant stock price decline and investor losses [1][5][6]. Summary by Sections Lawsuit Announcement - The Law Offices of Frank R. Cruz are encouraging Baxter shareholders to inquire about a class action lawsuit filed on behalf of investors who purchased Baxter common stock between February 23, 2022, and July 30, 2025 [1][2]. Safety Issues - On April 7, 2025, a Missouri news outlet reported serious safety concerns regarding Baxter's Novum IQ Large Volume Pump, citing a whistleblower who claimed the pumps were unsafe for patient treatment [3]. - Following this, Baxter issued warning letters about potential underinfusion risks, later revealing 79 reports of serious injuries and two patient deaths associated with the device [4]. Stock Price Impact - On July 31, 2025, Baxter announced a voluntary pause on shipments and installations of the Novum LVP, resulting in a stock price drop of $6.24, or 22.4%, closing at $21.61 per share [5]. Allegations in the Lawsuit - The lawsuit alleges that Baxter made materially false and misleading statements and failed to disclose critical information about the Novum LVP's systemic defects, which posed risks of serious injury or death to patients [6][7]. - Specific allegations include the company's knowledge of device malfunctions, inadequate remedial measures, and misleading positive statements about its business prospects [7].

Core Insights - Baxter International Inc. (BAX) is set to release its third-quarter 2025 results on October 30, with expectations of modest growth despite recent mixed performance [1][3] Q3 Estimates - The consensus estimate for revenues is $2.87 billion, reflecting a 6.4% increase from the prior-year quarter [2] - Earnings per share (EPS) is projected at 60 cents, indicating a 25% year-over-year decline [2] Important Factors to Note - The company experienced a 4% growth in sales from continuing operations in the second quarter, supported by Drug Compounding, Advanced Surgery, and Care & Connectivity Solutions, but faced challenges in Infusion Therapies & Technologies and Injectables & Anesthesia [3] - Adjusted EPS for the second quarter was 59 cents, at the low end of guidance, while operating margin improved by 180 basis points to 15.1% [3] Management Expectations - For Q3, management anticipates revenue growth of 6-7% and operational growth of 3-4%, aided by foreign exchange tailwinds and approximately $80 million in MSA revenues from Vantive [4] - Adjusted EPS is expected to range between 58-62 cents, with margin stability anticipated despite volume pressures in IV solutions [4] Segmental Overview - **Medical Products & Therapies (MPT)**: Second-quarter sales rose 1% operationally to $1.3 billion, with Advanced Surgery growth offset by weakness in ITT [6] - **Healthcare Systems & Technologies (HST)**: Revenues increased 2% to $767 million, driven by 4% growth in CCS, with international strength [9] - **Pharmaceuticals**: Sales grew 1% to $612 million, with Drug Compounding growth offsetting declines in Injectables and anesthesia [10] - **Other Sales & Transitional Revenues**: Other sales totaled $13 million, with MSA revenues from Vantive contributing $98 million; projected MSA revenues for Q3 are nearly $80 million [11] Earnings Prediction Insights - The current model does not predict an earnings beat for Baxter, as the Earnings ESP is 0.00% [12] - Baxter holds a Zacks Rank of 3, indicating a hold position [13]

Core Points - A class action lawsuit has been filed against Baxter International, Inc. for alleged securities fraud and unlawful business practices [2] - Baxter announced a voluntary and temporary pause in shipments and installations of its Novum LVP medical device, impacting its stock price significantly [2] Company Overview - Baxter International, Inc. is involved in the medical device sector, specifically focusing on intravenous fluid delivery systems [2] - The company has offered an alternative product, the Spectrum infusion pump, to customers affected by the pause in Novum LVP shipments [2] Financial Impact - Following the announcement of the shipment pause, Baxter's stock price dropped by $6.29 per share, representing a 22.4% decline, closing at $21.76 per share on July 31, 2025 [2]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Baxter International Inc. due to allegations of false and misleading statements regarding the safety and efficacy of its Novum LVP product, which has led to significant investor losses [1][3]. Summary by Relevant Sections Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in Baxter between February 23, 2022, and July 30, 2025, to discuss their legal rights [1]. - The firm has set a deadline of December 15, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against Baxter [1]. Allegations Against Baxter - The complaint alleges that Baxter and its executives violated federal securities laws by failing to disclose systemic defects in the Novum LVP, which caused malfunctions and posed risks to patients [3]. - Specific issues included underinfusion, overinfusion, and complete non-delivery of fluids, which led to serious injuries and deaths [3]. - Baxter's attempts to address these defects were deemed inadequate, and the company faced a heightened risk of halting sales of the Novum LVP [3]. Impact on Stock Performance - The extent of the alleged fraud was revealed on July 31, 2025, when Baxter announced a voluntary pause in shipments and installations of the Novum LVP, resulting in a 22.4% drop in stock price, closing at $21.76 [4]. Class Action Participation - The lead plaintiff in a class action is defined as the investor with the largest financial interest who directs the litigation on behalf of the class [5]. - Members of the putative class can choose to serve as lead plaintiff or remain absent, with their ability to recover not affected by this decision [5]. Additional Information - Faruqi & Faruqi encourages anyone with information regarding Baxter's conduct, including whistleblowers and former employees, to contact the firm [5].